ATE229007T1 - 6-benzyl-2h-pyridazin-3-on derivate,deren herstellung und deren verwendung als inhibitoren der prostaglandin g/h synthase i and ii (cox i and cox ii) - Google Patents

6-benzyl-2h-pyridazin-3-on derivate,deren herstellung und deren verwendung als inhibitoren der prostaglandin g/h synthase i and ii (cox i and cox ii)

Info

Publication number
ATE229007T1
ATE229007T1 AT97108260T AT97108260T ATE229007T1 AT E229007 T1 ATE229007 T1 AT E229007T1 AT 97108260 T AT97108260 T AT 97108260T AT 97108260 T AT97108260 T AT 97108260T AT E229007 T1 ATE229007 T1 AT E229007T1
Authority
AT
Austria
Prior art keywords
cox
prostaglandin
pyridazine
synthase
inhibitors
Prior art date
Application number
AT97108260T
Other languages
English (en)
Inventor
Darin Arthur Allen
James Patrick Dunn
Eric Brian Sjogren
David Bernard Smith
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Application granted granted Critical
Publication of ATE229007T1 publication Critical patent/ATE229007T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/14—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT97108260T 1996-05-30 1997-05-22 6-benzyl-2h-pyridazin-3-on derivate,deren herstellung und deren verwendung als inhibitoren der prostaglandin g/h synthase i and ii (cox i and cox ii) ATE229007T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US1867296P 1996-05-30 1996-05-30

Publications (1)

Publication Number Publication Date
ATE229007T1 true ATE229007T1 (de) 2002-12-15

Family

ID=21789188

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97108260T ATE229007T1 (de) 1996-05-30 1997-05-22 6-benzyl-2h-pyridazin-3-on derivate,deren herstellung und deren verwendung als inhibitoren der prostaglandin g/h synthase i and ii (cox i and cox ii)

Country Status (13)

Country Link
US (1) US5886178A (de)
EP (1) EP0810218B1 (de)
JP (1) JP2790450B2 (de)
CN (1) CN1136197C (de)
AR (1) AR008377A1 (de)
AT (1) ATE229007T1 (de)
BR (1) BR9703332A (de)
CA (1) CA2205757C (de)
DE (1) DE69717537T2 (de)
DK (1) DK0810218T3 (de)
ES (1) ES2186821T3 (de)
PT (1) PT810218E (de)
TR (1) TR199700419A2 (de)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2590912T3 (es) 1997-12-08 2016-11-24 Merck Patent Gmbh Proteínas de fusión heterodiméricas útiles para inmunoterapia dirigida y estimulación general del sistema inmunitario
US20030105294A1 (en) * 1998-02-25 2003-06-05 Stephen Gillies Enhancing the circulating half life of antibody-based fusion proteins
ES2267263T3 (es) * 1998-04-15 2007-03-01 Emd Lexigen Research Center Corp. Coadministracion de un inhibidor de la angiogenesis para reforzar la respuesta inmunologica por medio de la mediacion de una proteina de fusion de una citoquina con un anticuerpo.
US6680344B1 (en) 1999-06-01 2004-01-20 The University Of Texas Southwestern Medical Center Method of treating hair loss using diphenylmethane derivatives
WO2000072810A1 (en) 1999-06-01 2000-12-07 The University Of Texas Southwestern Medical Center Method of treating hair loss using sulfonyl thyromimetic compounds
US7067110B1 (en) 1999-07-21 2006-06-27 Emd Lexigen Research Center Corp. Fc fusion proteins for enhancing the immunogenicity of protein and peptide antigens
SK782002A3 (en) 1999-07-21 2003-08-05 Lexigen Pharm Corp FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens
MXPA02001417A (es) * 1999-08-09 2002-08-12 Lexigen Pharm Corp Complejos multiples de citosina-anticuerpo.
CA2391080A1 (en) 1999-11-12 2001-05-25 Merck Patent Gesellschaft Mit Beschraenkter Haftung Erythropoietin forms with improved properties
HUP0204475A2 (en) 2000-02-11 2003-04-28 Merck Patent Gmbh Enhancing the circulating half-life of antibody-based fusion proteins
KR20030064275A (ko) * 2000-06-29 2003-07-31 메르크 파텐트 게엠베하 면역싸이토카인 흡수 증강제와의 조합 치료에 의한항체-싸이토카인 융합 단백질 매개 면역 반응 증강
US7151102B2 (en) * 2000-10-30 2006-12-19 Kudos Pharmaceuticals Limited Phthalazinone derivatives
RU2003129528A (ru) * 2001-03-07 2005-04-10 Мерк Патент ГмбХ (DE) Способ экспрессии белков, содержащих в качестве компонента гибридный изотип антитела
WO2002079415A2 (en) * 2001-03-30 2002-10-10 Lexigen Pharmaceuticals Corp. Reducing the immunogenicity of fusion proteins
EP1383785B1 (de) 2001-05-03 2011-03-16 Merck Patent GmbH Rekombinanter, tumorspezifischer antikörper und dessen verwendung
DK1454138T3 (da) * 2001-12-04 2012-02-13 Merck Patent Gmbh Immunocytokiner med moduleret selektivitet
DE60335359D1 (de) * 2002-04-30 2011-01-27 Kudos Pharm Ltd Phthalazinonderivate
WO2004055056A1 (en) * 2002-12-17 2004-07-01 Merck Patent Gmbh Humanized antibody (h14.18) of the mouse 14.18 antibody binding to gd2 and its fusion with il-2
US7449464B2 (en) * 2003-03-12 2008-11-11 Kudos Pharmaceuticals Limited Phthalazinone derivatives
GB0305681D0 (en) 2003-03-12 2003-04-16 Kudos Pharm Ltd Phthalazinone derivatives
CN100469769C (zh) * 2003-03-24 2009-03-18 弗·哈夫曼-拉罗切有限公司 作为逆转录酶抑制剂的苄基-哒嗪酮
JP4627315B2 (ja) * 2004-03-23 2011-02-09 エフ．ホフマン−ラ ロシュ アーゲー 非ヌクレオシド逆転写酵素阻害剤としてのベンジルピリダジノン誘導体
WO2005100323A1 (en) * 2004-04-15 2005-10-27 F. Hoffmann-La Roche Ag Process for preparing pyridazinone compounds
GB0419072D0 (en) * 2004-08-26 2004-09-29 Kudos Pharm Ltd Phthalazinone derivatives
JP2008510783A (ja) * 2004-08-26 2008-04-10 クドス ファーマシューティカルズ リミテッド ４−ヘテロアリールメチル置換フタラジノン誘導体
GB0428111D0 (en) * 2004-12-22 2005-01-26 Kudos Pharm Ltd Pthalazinone derivatives
CA2623728A1 (en) * 2005-09-30 2007-04-12 F. Hoffmann-La Roche Ag Nnrt inhibitors
GB0521373D0 (en) * 2005-10-20 2005-11-30 Kudos Pharm Ltd Pthalazinone derivatives
GB0610680D0 (en) * 2006-05-31 2006-07-12 Istituto Di Ricerche D Biolog Therapeutic compounds
US20090181951A1 (en) * 2006-06-15 2009-07-16 Kudos Pharmaceuticals Limited Parp inhibitors
WO2007144639A1 (en) * 2006-06-15 2007-12-21 Kudos Pharmaceuticals Limited 2 -oxybenzamide derivatives as parp inhibitors
US20090281086A1 (en) * 2006-06-15 2009-11-12 Kudos Pharmaceuticals Limited 2 -oxyheteroarylamide derivatives as parp inhibitors
US20080280910A1 (en) * 2007-03-22 2008-11-13 Keith Allan Menear Phthalazinone derivatives
TW200900396A (en) * 2007-04-10 2009-01-01 Kudos Pharm Ltd Phthalazinone derivatives
US20090023727A1 (en) * 2007-07-05 2009-01-22 Muhammad Hashim Javaid Phthalazinone derivatives
MX2010002749A (es) 2007-09-14 2010-06-25 Astrazeneca Ab Derivados de ftalazinona.
CA2702429A1 (en) * 2007-10-17 2009-04-23 Kudos Pharmaceuticals Limited Crystalline form l 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2h-phthalazin-1-one
EP2220073B1 (de) * 2007-11-15 2014-09-03 MSD Italia S.r.l. Pyridazinonderivate als parp-inhibitoren
UY31603A1 (es) 2008-01-23 2009-08-31 Derivados de ftalazinona
CA2737400C (en) * 2008-10-07 2016-11-22 Astrazeneca Uk Limited Pharmaceutical formulation 514
US20110015393A1 (en) * 2009-07-15 2011-01-20 Astrazeneca Ab Phthalazinone compound
GB201219820D0 (en) 2012-11-05 2012-12-19 Isis Innovation Compounds
ES2544869B2 (es) * 2014-03-04 2016-01-18 Universidade De Vigo Derivados de piridazin-3(2H)-ona inhibidores selectivos de la isoforma B de la monoaminooxidasa
CN111153859B (zh) * 2015-04-15 2021-09-03 江苏恩华药业股份有限公司 哒嗪酮类衍生物及其应用
MY196801A (en) * 2016-03-04 2023-05-03 Otsuka Pharma Co Ltd 5-methyl-6-phenyl-4,5-dihydro-2h-pyridazin-3-one derivative

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3752826A (en) * 1970-01-26 1973-08-14 Mcneilab Inc Aroyl substituted pyrroles
US4599332A (en) * 1983-12-07 1986-07-08 Warner-Lambert Company 4,5-dihydro-6-[2-[4-(1H-imidazol-1-yl)phenyl]-ethenyl]-3(2H)-pyridazinones and related compounds
IE913866A1 (en) * 1990-11-28 1992-06-03 Ici Plc Aryl derivatives
US5622948A (en) * 1994-12-01 1997-04-22 Syntex (U.S.A.) Inc. Pyrrole pyridazine and pyridazinone anti-inflammatory agents

Also Published As

Publication number Publication date
DE69717537D1 (de) 2003-01-16
PT810218E (pt) 2003-03-31
EP0810218B1 (de) 2002-12-04
CA2205757A1 (en) 1997-11-30
CN1136197C (zh) 2004-01-28
TR199700419A2 (xx) 1997-12-21
JPH1045723A (ja) 1998-02-17
EP0810218A1 (de) 1997-12-03
AR008377A1 (es) 2000-01-19
JP2790450B2 (ja) 1998-08-27
ES2186821T3 (es) 2003-05-16
DK0810218T3 (da) 2003-03-24
US5886178A (en) 1999-03-23
CA2205757C (en) 2006-01-24
CN1169426A (zh) 1998-01-07
BR9703332A (pt) 1998-09-22
DE69717537T2 (de) 2003-11-06

Similar Documents

Publication Publication Date Title
ATE229007T1 (de) 6-benzyl-2h-pyridazin-3-on derivate,deren herstellung und deren verwendung als inhibitoren der prostaglandin g/h synthase i and ii (cox i and cox ii)
ATE315553T1 (de) 4-aminothiazol derivate, deren herstellung und deren verwendung als inhibitoren cyclin- abhängiger kinasen
ATE421954T1 (de) Heteroaryl-hexansäureamid-derivate, ihre herstellung und ihre verwendung als selektive inhibitoren der bindung von mip-1-alpha an seinen ccr1 rezeptor
ATE243682T1 (de) Heterozyklisch substituierte biphenylamid derivate, deren herstellung und deren verwendung als fungizide
DE69718351D1 (de) Diaminobenzoesäure derivate als farbstoffvorläufer
DE60118975D1 (de) Tetrahydropyridinderivate, deren herstellung und deren verwendung als inhibitoren der zellproliferation
ATE286021T1 (de) Substituierte phenylderivate, ihre herstellung und verwendung
DE69623992D1 (de) Derivate von dolestatin, deren herstellung und verwendung
DE69806831D1 (de) Dithiolan Derivate, deren Herstellung und deren Heileffekt
ATE216360T1 (de) Sulfinsäurederivate und deren herstellung und verwendung
DE69719193D1 (de) Substituierte pyrido- oder pyrimidogruppen enthaltende 6,6- oder 6,7-bicyclische derivate
ATE330955T1 (de) Indolderivate und deren verwendung als inhibitoren der phosphodiesterase 4.
ATE252575T1 (de) Indole und 2,3-dihydroindolderivate, ihre herstellung und verwendung
DE69839939D1 (de) Tropoelastinderivate
FI965074A7 (fi) Tropaani-2-aldoksiinijohdannaisia hermoston välittäjäaineiden takaisinoton estäjinä
DE60009155D1 (de) Substituierte phenyl-piperazin-derivate, deren herstellung und verwendung
ATE229034T1 (de) 3-mercaptoacetylamino-1,5-substituierte-2-oxo- azepan derivate und deren verwendung als inhibitoren von matrix-metalloproteinasen
ATE237585T1 (de) Substituierte 3,3-diamino-2-propennitrile, ihre herstellung und verwendung
ATE268760T1 (de) Neue carbonsäurederivate, ihre herstellung und verwendung
DE59802922D1 (de) 3-substituierte tetrahydropyridopyrimidinon-derivate, ihre herstellung und verwendung
DE69911243D1 (de) Benzofuranderivate, ihre herstellung und verwendung
NO990913L (no) Naftylforbindelser, intermediater, sammensetninger og metoder for anvendelse
ATE224382T1 (de) Furan- und thiophencarbothioamid derivate, deren herstellung und deren verwendung als inhibitoren der replikation von hiv-1 und hiv-1 mutanten
NO985685D0 (no) Dibenzo-oksazepin- og -dioksazepin-derivater og deres anvendelse som anti-tumormidler
EE9900585A (et) 6-asauratsiili derivaadid IL-5 inhibiitoritena

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0810218

Country of ref document: EP

REN Ceased due to non-payment of the annual fee